Perimeter's diagnostic capabilities allow for early detection of CNV

Article

The Foresee PHP, a second-generation Preferential Hyperacuity Perimeter is available for improved detection and early diagnosis of the most aggressive and sight-threatening form of age-related macular degeneration (AMD). Developed by Notal Vision and distributed exclusively in the United States by MSS, the device represents a technologic leap for monitoring AMD and is a clinically validated diagnostic device for improved early detection of choroidal neovascularization (CNV).

The Foresee PHP, a second-generation Preferential Hyperacuity Perimeter, is available for improved detection and early diagnosis of the most aggressive and sight-threatening form of age-related macular degeneration (AMD). Developed by Notal Vision and distributed exclusively in the United States by MSS, the device represents a technologic leap for monitoring AMD and is a clinically validated diagnostic device for improved early detection of choroidal neovascularization (CNV).

The device is the follow-up to the Preview PHP and allows eye-care professionals to track any changes to a patient's visual field resulting from the advancement of AMD. The updated device is completely automated, allowing for patient self-operation, while still exhibiting high sensitivity and specificity. The Foresee PHP also has a larger normative database, provides faster testing and test analysis, and generates advanced reports that feature a map of the patient's visual field indicating the relative location of abnormalities in the macular area.

The Foresee PHP maps defects within a patient's visual field by analyzing responses to "dot deviation signals" flashing on a computer screen. The patient uses a stylus pen to touch the screen to identify the most prominent distortion in the line. The response patterns are recorded, analyzed and compared with the normative database, producing a report revealing the relative location of the defects in the macular area.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.